Safety and Efficacy of Oral Direct Factor Xa Inhibitors in Patients With Nephrotic Syndrome: Results From a National Retrospective Study
Authors:
Open Access
- 3 February 2025
- journal article
- Published by Elsevier in Kidney International Reports
- Vol. 10 (4) , 1188-1195
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular DiseasesKidney International, 2021
- Albumin and bleed risk in rivaroxaban treated patientsJournal of Thrombosis and Thrombolysis, 2020
- Role of direct oral anticoagulants in patients with kidney diseaseKidney International, 2020
- A Systematic Review of Prophylactic Anticoagulation in Nephrotic SyndromeKidney International Reports, 2020
- Direct-Acting Oral Anticoagulants as Prophylaxis Against Thromboembolism in the Nephrotic SyndromeKidney International Reports, 2018
- Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixabanThe Journal of Clinical Pharmacology, 2015
- Predictors of Gastrointestinal Bleeding Among Patients with Atrial Fibrillation After Initiating Dabigatran TherapyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2015
- Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral AnticoagulantsJACC, 2014
- Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathyKidney International, 2014
- Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritisKidney International, 2012